/
/
/

Accretion Pharmaceuticals Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---56%
---42%
---259%
41%41%41%29%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
ACCPL-ST
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,769.9₹424202 Cr38.688.2958.23₹11479 Cr
10,064₹264141 Cr90.334.04128.41₹2568 Cr
4,650₹174402 Cr82.1114.04106.21₹2163 Cr
2,323₹126811 Cr94.648.1733.94₹889 Cr
1,240.6₹123685 Cr27.419.4262.53₹5040 Cr
1,368.3₹111868 Cr39.9511.0859.2₹4196 Cr
1,396.9₹111650 Cr38.5410.8652.6₹3879 Cr
2,475₹102196 Cr45.5717.2376.26₹1913 Cr
1,694.5₹96951 Cr26.1117.9596.84₹3505 Cr
2,015.9₹91301 Cr16.5130.95154.35₹5333 Cr
209.5₹222 Cr22.94—9.79₹10 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024
———
₹11 Cr₹8 Cr₹4 Cr
₹44 Cr₹7 Cr₹1 Cr
₹44 Cr₹7 Cr₹1 Cr
₹55 Cr₹15 Cr₹5 Cr
₹0₹23 L₹1 Cr
₹86 L₹94 L₹6 Cr
₹27 L₹19 L₹14,000
₹1 Cr₹1 Cr₹7 Cr
———
₹6 Cr₹8 Cr₹7 Cr
₹3 Cr₹4 Cr₹2 Cr
₹9 Cr₹9 Cr₹4 Cr
₹4 Cr₹3 Cr₹2 Cr
₹21 Cr₹23 Cr₹15 Cr
₹77 Cr₹40 Cr₹27 Cr
₹12 Cr₹14 Cr₹13 Cr
———
₹15 Cr₹7 Cr₹5 Cr
₹2 Cr₹100 L₹22 L
₹13 Cr₹6 Cr₹5 Cr
₹20 L₹0₹0
₹31 L₹23 L₹0
₹0₹66,000₹13 L
₹14 Cr₹6 Cr₹5 Cr
———
₹28 Cr₹21 Cr₹14 Cr
₹22 Cr₹12 Cr₹6 Cr
₹4 Cr₹5 L₹9 L
₹2 L₹2 L₹6 L
₹6 Cr₹1 Cr₹2 Cr
₹60 Cr₹33 Cr₹22 Cr
₹40 Cr₹10 Cr₹7 Cr
₹3 Cr₹10 L₹0
₹77 Cr₹40 Cr₹27 Cr
₹47₹19₹14
₹47₹19₹7

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024
₹13 Cr₹10 Cr₹2 Cr
₹2 Cr₹2 Cr₹62 L
-₹26 Cr-₹10 Cr-₹15 Cr
-₹11 Cr₹2 Cr-₹12 Cr
-₹15 Cr-₹62 L-₹12 Cr
-₹9 Cr-₹2 Cr-₹5 Cr
₹27 Cr₹2 Cr₹17 Cr
₹4 Cr-₹4 L₹9 L
₹5 L₹9 L₹0
₹4 Cr₹5 L₹9 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)209.50
Volume (₹)16,200.00
High (₹)209.50
Upper Circuit209.50
Low (₹)209.00
Lower Circuit189.60
Prev Close199.55
52W High (₹)220.00
Price209.50
52W Low (₹)54.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)221.82 Cr
Div. Yield (%)0.00
PE Ratio22.94
Debt to Equity0.24
Price to Book1.35
Book Value46.91
EPS (TTM)8.70
Face Value10.00
ROE (%)28.72

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
ACCPL-STNSE
LTP
1W Low
1W High
Market cap (₹)
1769.9-7.8 (-0.44%)
1722
1855
4,24,202Cr
10064+284 (2.90%)
9621.50
10064
2,64,141Cr
4650+36.6 (0.79%)
4532
4675
1,74,402Cr
2323-82.5 (-3.43%)
2206.10
2441.90
1,26,811Cr
1240.6-4.9 (-0.39%)
1182
1254.20
1,23,685Cr
1368.3+16.3 (1.21%)
1336.70
1368.30
1,11,868Cr
1396.9+18 (1.31%)
1357
1396.90
1,11,650Cr
2475-17.8 (-0.71%)
2457.90
2528
1,02,196Cr
1694.5+13.1 (0.78%)
1647.20
1697.40
96,951Cr
2015.9+4.9 (0.24%)
1974
2033.80
91,301Cr
209.5+19.45 (10.23%)
188.95
209.50
222Cr

Accretion Pharmaceuticals Ltd Annual Results Key Takeaways

Basis: Consolidated annual results.

Accretion Pharmaceuticals Ltd Quaterly Results Key Takeaways